Companies › PMV Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rezatapopt p53 reactivator selective for TP53 Y220C mutation | TP53 | Phase 1 | Advanced Solid Tumor; TP53 Y220C Mutation; Myelodysplastic Syndrome | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04585750 | rezatapopt | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07372625 | rezatapopt | Phase 1 | TP53 Y220C Mutation | Oncology | Mar 2027 |
| NCT06616636 | rezatapopt | Phase 1 | Myelodysplastic Syndrome | Oncology | Aug 2027 |
Cash and short-term investments of $109m on 2026-09-30; operating cash outflow about $70m a year; runway about 18 months at that burn, to Apr 2028
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.